Table 1.
The antifungal susceptibility pattern of Aspergillus flavus isolates
| Aspergillus flavus | Antifungal | Minimum inhibitory concentration (μg/mL) | R (%) | %ECVa | |||
|---|---|---|---|---|---|---|---|
| MIC | MIC50/ | MIC90/ | MICGM | ||||
| Clinical isolates (20) | LUL | 0.00049–0.00781 | 0.00195 | 0.00391 | 0.00244 | ND | ND |
| AMB | 16–64 | 32 | 64 | 44 | 20 (100) | 0.0% | |
| CASb | 0.0625–4 | 0.25 | 2 | 0.24 | 10 (50) | 50% | |
| VRC | 0.0625–1 | 0.125 | 0.5 | 0.76 | 0 (0.0) | 100% | |
| Environmental isolates (18) | LUL | 0.00195–0.00781 | 0.00391 | 0.00391 | 0.00336 | ND | ND |
| AMB | 8–32 | 32 | 32 | 24.4 | 18 (100) | 0.0% | |
| CASb | 0.0625–4 | 0.25 | 4 | 0.44 | 5 (27.8) | 72.2% | |
| VRC | 0.125–2 | 0.5 | 1 | 0.5 | 0 (0.0) | 100% | |
| All isolates (38) | LUL | 0.00049–0.00781 | 0.00195 | 0.00391 | 0.00288 | ND | ND |
| AMB | 8–64 | 32 | 64 | 33.8 | 38 (100) | 0.0% | |
| CAS b | 0.0625–4 | 0.25 | 1 | 0.55 | 15 (39.5) | 60.5% | |
| VRC | 0.0625–2 | 0.25 | 0.5 | 0.34 | 0 (0.0) | 100% | |
LUL, Luliconazole; AMB, Amphotericin B; CAS, Caspofungin; VRC, Voriconazole; GM, Geometric mean; R, Resistance; ND, not determined (no ECVs were available).
a
%MICs less than or equal to than the epidemiologic cutoff values (ECVs) (ECV = 4 μg/ml for amphotericin B, 2 μg/ml for voriconazole, 0.5 μg/ml for caspofungin.
b
Minimum effective concentration (MEC), MEC50, MEC90 and MECGM were calculated for Aspergillus flavus.